For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 262,149 | 305,871 | 270,153 | 383,729 |
| Revenues | - | - | - | 0 |
| Research and development | 117,064 | 34,942 | 20,454 | 14,430 |
| Stock-based compensation | 210,016 | 281,246 | 277,226 | 250,189 |
| Total operating expenses | 589,229 | 622,059 | 567,833 | 648,348 |
| Interest expense, net | 1,260 | 1,068 | 958 | 1,070 |
| Net loss | -590,489 | -623,127 | -568,791 | -649,418 |
| Basic EPS | -0.03 | -0.033 | -0.03 | -0.034 |
| Diluted EPS | -0.03 | -0.033 | -0.03 | -0.034 |
| Basic Average Shares | 18,754,739 | 18,821,710 | 18,579,776 | 18,326,587 |
| Diluted Average Shares | 18,754,739 | 18,821,710 | 18,579,776 | 18,326,587 |
RetinalGenix Technologies Inc. (RTGN)
RetinalGenix Technologies Inc. (RTGN)